Home Cart Sign in  
Chemical Structure| 108549-23-1 Chemical Structure| 108549-23-1

Structure of 108549-23-1

Chemical Structure| 108549-23-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 108549-23-1 ]

CAS No. :108549-23-1
Formula : C20H28NO2P
M.W : 345.42
SMILES Code : CC(N(C(C)C)P(OCC1=CC=CC=C1)OCC2=CC=CC=C2)C
MDL No. :MFCD00191988
InChI Key :ANPWLBTUUNFQIO-UHFFFAOYSA-N
Pubchem ID :196621

Safety of [ 108549-23-1 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 108549-23-1 ] Show Less

Physicochemical Properties

Num. heavy atoms 24
Num. arom. heavy atoms 12
Fraction Csp3 0.4
Num. rotatable bonds 9
Num. H-bond acceptors 3.0
Num. H-bond donors 0.0
Molar Refractivity 102.59
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

35.29 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

4.2
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

4.85
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

5.46
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

3.79
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

4.52
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

4.56

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-4.81
Solubility 0.00531 mg/ml ; 0.0000154 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-5.33
Solubility 0.00163 mg/ml ; 0.00000473 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-6.26
Solubility 0.000189 mg/ml ; 0.000000548 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Poorly soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

Yes
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

Yes
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

Yes
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-4.96 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<2.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

4.04

Application In Synthesis of [ 108549-23-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 108549-23-1 ]

[ 108549-23-1 ] Synthesis Path-Downstream   1~5

  • 1
  • [ 873054-44-5 ]
  • [ 108549-23-1 ]
  • C38H41N2O5P [ No CAS ]
YieldReaction ConditionsOperation in experiment
With 1H-tetrazole; In dichloromethane; acetonitrile; at 20℃; for 2h; Example 1 [5-[(4-oxo-1H-quinolin-3-yl)carbonylamino]-2,4-ditert-butyl-phenoxy]phosphonic acid dibenzyl ester Tetrazole (0.45 M solution in CH3CN, 1.24 mL, 0.56 mmol) was added to a mixture of N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (78 mg, 0.2 mmol) and dibenzyl diisopropylphosphoramidite (184 muL, 0.56 mmol) in dichloromethane (2 mL) and the reaction was stirred at room temperature for 2 h, then tert-butyl hydroperoxide (5.5M solution in decane, 102 muL, 0.56 mmol) was added and the reaction was stirred at room temperature overnight. The reaction mixture was then partitioned between ethyl acetate and saturated NaHCO3 solution. The organic layer was washed with brine, dried over MgSO4 and concentrated. The residue was adsorbed onto silica gel and purified by column chromatography (silica gel, 50-100% ethyl acetate-hexanes) to yield [5-[(4-oxo-1H-quinolin-3-yl)carbonylamino]-2,4-ditert-butyl-phenoxy]phosphonic acid dibenzyl ester as a clear oil (80 mg, 61%). 1H-NMR (400 MHz, d-DMSO) delta 13.04 (br s, 1H), 12.05 (s, 1H), 8.91 (s, 1H), 8.35 (dd, J=8.1, 1.0 Hz, 1H), 7.88 (s, 1H), 7.82 (m, 1H), 7.77 (d, J=7.7 Hz, 1H), 7.53 (m, 1H), 7.37-7.31 (m, 11H), 5.19 (m, 4H), 1.44 (s, 9H), 1.33 (s, 9H); HPLC ret. time 3.77 min, 30-99% CH3CN, 5 min run; ESI-MS 653.4 m/z [M+H]+.
  • 2
  • [ 108549-23-1 ]
  • [ 1277151-44-6 ]
  • 3
  • [ 108549-23-1 ]
  • [ 108149-63-9 ]
  • [ 1415820-89-1 ]
YieldReaction ConditionsOperation in experiment
With 1H-tetrazole; In acetonitrile; for 1h; Scheme 21Dibenzyl diisopropylphosphoramidite (1.067 mL, 3.24 mmol) is added to te/ -butyl (4S)-4- (hydroxymethyl)-2,2-dimethyl-1 ,3-oxazolidine-3-carboxylate (0.5 g, 2.162 mmol) (106) [prepared from D-serine as described for the enantiomer in Organic Syntheses, Coll. Vol. 10, p. 320 (2004) and Vol. 77, p. 64 (2000)] and 1H-tetrazole (0.454 g, 6.49 mmol) in CH3CN (10 mL) and the mixture stirred for 1 h. The solvent is evaporated and the residue flash chromatographed (EtOAc-hexanes, 1 :9 v/v) to give tert-butyl (4R)-4- ([bis(benzyloxy)phosphanyl]oxy}methyl)-2,2-dimethyl-1 ,3-oxazolidine-3-carboxylate as a colourless oil. This is dissolved in CH2CI2 (10 mL) cooled in ice-water and MCPBA (m- chloroperoxybenzoic acid) (0.995 g, 4.32 mmol) added and stirred for 30 min. The mixture is diluted with CH2CI2 (50 mL) and washed with sat. aq. Na2S03, sat. aq. NaHC03 (3x) then brine, dried and the solvent evaporated. The residue is flash chromatographed (DCM-hexanes-EtOAc, 4:3:1 v/v/v) to give terf-butyl (4R)-4- ([bis(benzyloxy)phosphoryl]oxy}methyl)-2,2-dimethyl-1 ,3-oxazolidine-3-carboxylate(107) as a colourless oil (0.816 g, 77%). [a]^2 +21.5 (c 0.57, CHCI3). 1H NMR (500 MHz, CDCI3) 7.34 (s, 10H), 5.08-5.00 (m, 4H), 4.22-4.16 (m, 0.5H), 4.13-4.06 (m, 1 H), 3.97- 3.83 (m, 3H), 3.77 (q, J = 8.6, 0.5H), 1.52-1.41 (m, 15H). 13C NMR (125.7 MHz) 152.1 , 151.4 (C), 135.7 (C), 128.6 (CH), 127.9 (CH), 94.1 , 93.6 (C), 80.6, 80.3 (C), 69.4 (CH2j, 65.7, 65.3 (CH2), 64.8, 64.6 (CH2), 56.6, 56.5, 56.32, 56.26 (CH), 28.3 (CH3), 27.4, 24.3 (CH3), 26.6, 23.0 (CH3). Referenced to the centre line of CDCI3 at delta 77.0. 31 P NMR (202.3 MHz, CDCI3) -1.0 (s), -1.1 (s). ESI-HRMS for C25H34NNa07P [M+Na]+ calcd 514.1971 ; found 514.1968. The NMR spectra indicated (107) is a ~1 :1 mixture of conformational isomers.
With 1H-tetrazole; In acetonitrile; for 1h; Dibenzyl diisopropylphosphoramidite (1.067 mL, 3.24 mmol) is added to compound 8540,41 (0.5 g, 2.162 mmol) and 1H-tetrazole (0.454 g, 6.49 mmol) in CH3CN (10 mL) and the mixture stirred for 1 h. The solvent is evaporated and the residue flash chromatographed (EtOAc-hexanes, 1:9 v/v) to give tert-butyl (4R)-4-([bis(benzyloxy)phosphanyl]oxy}methyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate as a colourless oil. This is dissolved in CH2Cl2 (10 mL) cooled in ice-water and MCPBA (m-chloroperoxybenzoic acid) (0.995 g, 4.32 mmol) added and stirred for 30 min. The mixture is diluted with CH2Cl2 (50 mL) and washed with satd aq Na2SO3, satd aq NaHCO3 (3*) then brine, dried and the solvent evaporated. The residue is flash chromatographed (DCM-hexanes-EtOAc, 4:3:1 v/v/v) to give tert-butyl (4R)-4-([bis(benzyloxy)phosphoryl]oxy}methyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate as a colourless oil (0.816 g, 77%). [alpha]22D +21.5 (c 0.57, CHCl3). 1H NMR (500 MHz, CDCl3) 7.34 (s, 10H), 5.08-5.00 (m, 4H), 4.22-4.16 (m, 0.5H), 4.13-4.06 (m, 1H), 3.97-3.83 (m, 3H), 3.77 (q, J = 8.6, 0.5H), 1.52-1.41 (m, 15H). 13C NMR (125.7 MHz) 152.1, 151.4 (C), 135.7 (C), 128.6 (CH), 127.9 (CH), 94.1, 93.6 (C), 80.6, 80.3 (C), 69.4 (CH2), 65.7, 65.3 (CH2), 64.8, 64.6 (CH2), 56.6, 56.5, 56.32, 56.26 (CH), 28.3 (CH3), 27.4, 24.3 (CH3), 26.6, 23.0 (CH3). Referenced to the centre line of CDCl3 at delta 77.0. 31P NMR (202.3 MHz, CDCl3) -1.0 (s), -1.1 (s). ESI-HRMS for C25H34NNaO7P [M+Na]+ calcd 514.1971; found 514.1968. This material (0.77 g, 1.567 mmol) and 10% Pd-C (100 mg) are stirred in EtOH (15 mL) under a hydrogen atmosphere at ambient temperature and pressure for 16 h. The mixture is filtered through cellulose paper and the solvent is evaporated to give [(4R)-3-[(tert-butoxy)carbonyl]-2,2-dimethyl-1,3-oxazolidin-4-yl]methoxy}phosphonic acid as a colourless gum (480 mg). This is dissolved in 80% aq TFA (10 mL) and left at room temperature for 2 h. The solvent is evaporated and the residue dissolved in H2O (10 mL) and washed with CH2Cl2 (2 * 10 mL) then evaporated. The residue is dissolved in H2O and chromatographed on RP 18 silica gel (H2O) to give 86 as a colourless gum which solidified (0.26 g, 97%). [alpha]22D 0 (c 0.565, H2O). No measurable rotation observed. 1H NMR (500 MHz, D2O) 4.19-4.12 (m, 1H), 4.11-4.03 (m, 1H), 3.90 (dd, J = 12.3, 4.7, 1H), 3.81 (dd, J = 12.3, 6.7, 1H), 3.63 (m, 1H). Referenced to HOD at delta 4.79. 13C NMR (125.7 MHz, D2O) 62.9 (d, J = 3.2, CH2), 59.1 (CH2), 53.5 (d, J = 7.4, CH). Referenced to internal CH3CN at delta delta 1.47. 31P NMR (202.3 MHz, D2O) 0.0 (s). ESI-HRMS for C3H9NO5P [M-H]- calcd 170.0218; found 170.0211.
  • 4
  • [ 108549-23-1 ]
  • [ 198904-31-3 ]
  • methyl ((5S,8S,9S,14S)-8-benzyl-9-((bis(benzyloxy)phosphoryl)-oxy)-5-(tert-butyl)-15,15-dimethyl-3,6,13-trioxo-11-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,11,12-tetraazahexadecan-14-yl)carbamate [ No CAS ]
  • 5
  • [ 33689-29-1 ]
  • [ 108549-23-1 ]
  • methyl 1-((bis(benzyloxy)phosphoryl)oxy)cyclopropanecarboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
70.1% A mixture of methyl l-hydroxycyclopropanecarboxylate (1.1 g, 9.47 mmol), dibenzyl N A-diisopropylphosphoramidite (4.77 mL, 14.21 mmol) and 1 //-tetrazole (0.45 M in acetonitrile) (31.6 mL, 14.21 mmol) was stirred at room temperatue for 8 h. The reaction was cooled to 0 C. was added hydrogen peroxide (0.581 mL, 18.95 mmol). The mixture was partitioned between ethyl acetate (100 mL) and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude material was purified by CombiFlash (silica gel 60-120 mesh; 30% ethyl acetate in hexane as eluent) to get methyl 1 -((/v.s(benzyloxy)phosphoryl)oxy) cyclopropanecarboxylate (2.5 g, 6.64 mmol, 70.1%) as a colorless oil. NMR (400 MHz, chloroform-^ d = 7.41 - 7.30 (m, 10H), 5.17 - 5.05 (m, 4H), 3.71 (s, 3H), 1.48 - 1.31 (m, 4H); LCMS (ES): m/z 378.0 [M + H]+.
 

Historical Records

Technical Information

Categories